Implications of genetic testing for the insurance industry: the UK example.
This report summarises the controversy of genetic tests and insurance, with a focus on the UK situation during the past decade. UK experience provides insight for future strategies to help people with genetic disadvantages make insurance provision for themselves and their families. Non-disclosure of genetic test results (already carried out for clinical purposes) may not benefit people at risk of genetic disorders or with positive genetic tests. The pressure of geneticists over a decade to prevent disclosure to insurers may have masked opportunities to use insurance to provide help for people with genetic disadvantages. To seize the opportunities now, there must be collaboration, not conflict. Politicians, geneticists, social scientists and all elements of the insurance industry can contribute to wise solutions.
Raeburn
Sandy
S
Centre for Medical Genetics, University of Nottingham, Nottingham NG5 1PB, UK. sandy.raeburn@nottingham.ac.uk
D026683:Advisory Committees; D030881:Disclosure; D030342:Genetic Diseases, Inborn; D020022:Genetic Predisposition to Disease; D030661:Genetic Privacy; D005820:Genetic Testing / Q000639:trends*; D006801:Humans; D007341:Insurance / Q000458:organization & administration / Q000592:standards / Q000639:trends*; D015273:Insurance Selection Bias; D007348:Insurance, Health; D007352:Insurance, Life; D011237:Predictive Value of Tests; D011049:Social Control Policies / Q000639:trends*; D006113:United Kingdom